Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A Gemelli-IRCCS, Istituto di Radiologia, Universita' Cattolica del Sacro Cuore, L. go A. Gemelli 8, 00168, Rome, Italy.
Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Universitario A Gemelli-IRCCS, Universita' Cattolica del Sacro Cuore, L. go A. Gemelli 8, 00168, Rome, Italy.
Cardiovasc Intervent Radiol. 2020 Nov;43(11):1702-1707. doi: 10.1007/s00270-020-02583-6. Epub 2020 Jul 16.
Purpose To evaluate the feasibility, safety and efficacy of a combined single-step therapy in patients with unresectable single large (> 5 cm) hepatocellular carcinoma (HCC), with balloon-occluded microwave ablation (b-MWA) plus transcatheter arterial balloon-occluded chemoembolization (b-TACE).
MATERIALS & METHODS: Five consecutive Child A patients (mean age: 71.4 ± 3.2 yo; range 68-76 yo) with an unresectable single large HCC (> 5 cm) (mean size: 5.7 ± 0.6 cm; range 5.1-6.5 cm) were enrolled in our pilot study. The schedule consisted of percutaneous microwave ablation of the lesion during balloon occlusion of the hepatic artery supplying the tumor (b-MWA), followed by TACE under the occlusion of feeding arteries by a microballoon catheter (b-TACE). Adverse events and intra- and peri-procedural complications were clinically assessed. Early local efficacy was evaluated on 1- and 6-month follow-up multiphasic computed tomography (CT) on the basis of m-RECIST criteria.
Technical success was obtained in all procedures. No major complications occurred. A mean necrotic area of 6.8 ± 0.47 cm (range 6.3-7.4 cm) was obtained, with a complete response at 1-month follow-up obtained in 4 out of 5 lesions, with 1 partial response (less than 30% of residual tumor), successfully treated with a single TACE treatment. No residual tumor or local recurrence was registered at 6-month CT follow-up.
Our preliminary experience seems to demonstrate that b-MWA plus b-TACE could be a safe and effective combined therapy for unresectable large HCC lesions, allowing a high rate of local response also in lesion exceeding 5 cm in size.
目的 评估球囊阻断微波消融(b-MWA)联合经导管肝动脉球囊阻断化疗栓塞(b-TACE)在不能切除的单个大(>5cm)肝细胞癌(HCC)患者中联合一步治疗的可行性、安全性和疗效。
材料与方法 连续 5 例 Child A 患者(平均年龄:71.4±3.2 岁;年龄范围 68-76 岁),患有不能切除的单个大 HCC(>5cm)(平均大小:5.7±0.6cm;范围 5.1-6.5cm),纳入本研究。方案包括在肿瘤供血肝动脉球囊阻断期间进行经皮微波消融(b-MWA),然后在微球囊导管阻断供血动脉时进行 TACE(b-TACE)。临床评估不良事件和术中及围手术期并发症。根据 m-RECIST 标准,在 1 个月和 6 个月的多期 CT 随访时评估早期局部疗效。
结果 所有手术均获得技术成功。无重大并发症发生。平均坏死面积为 6.8±0.47cm(范围 6.3-7.4cm),5 个病灶中有 4 个在 1 个月随访时获得完全缓解,1 个部分缓解(残余肿瘤小于 30%),成功接受单次 TACE 治疗。6 个月 CT 随访时未发现残留肿瘤或局部复发。
结论 我们的初步经验似乎表明,b-MWA 联合 b-TACE 可能是一种安全有效的不能切除的大 HCC 病变联合治疗方法,即使病变大于 5cm,也能获得较高的局部反应率。